- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06149130
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xiong huihua
- Phone Number: 027-83663405
- Email: xionghuihua@hotmail.com
Study Contact Backup
- Name: Chao tengfei
- Phone Number: 027-83663409
- Email: turnface@126.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Recruiting
- Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology
-
Contact:
- Huihua Xiong, PI
- Phone Number: 027-83663405
- Email: xionghuihua@hotmail.com
-
Principal Investigator:
- Huihua Xiong, PI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Premenopausal/perimenopausal or postmenopausal women aged ≥18 years and ≤75 years;
- Histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER >10% tumor cell positive is defined as ER positive, PR >10% tumor cell positive is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 ++ but negative by FISH test, no amplification, defined as HER2 negative);
- Locally advanced breast cancer (radical local treatment is not possible) or recurrent metastatic breast cancer;
- Did not receive any systemic anti-cancer therapy at the stage of recurrence and metastasis or failed to receive first-line endocrine therapy at the advanced stage;
- Allowed to receive ≤1 line of chemotherapy
- Have at least one measurable lesion according to RECIST version 1.1
Adequate hematology and organ function, including:
hemoglobin > 9 g/dL without blood transfusion or erythropoietin in the past 14 days.
ANC ≥ 1.5×109/L without using granulocyte colony stimulating factor in the past 14 days.
PLT ≥ 75×109/L without blood transfusion in the past 14 days. TBIL ≤ 1.5 ×ULN (Gilbert syndrome allows ≤ 3 × ULN). ALT and AST ≤ 3 × ULN (if there is liver metastasis, ALT and AST ≤ 5 × ULN). Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
- ECOG score 0 or 1, and life expectancy ≥3 months;
- Fertile female subjects are required to use a medically approved contraceptive during the study treatment period and for at least 3 months after the last use of the study drug;
- Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
Exclusion Criteria:
- Previous use of CDK4/6 inhibitors or PD1/PD-L1 monoclonal antibody
- Uncontrolled central nervous system metastasis (meaning symptoms or the use of glucocorticoids or mannitol to control symptoms);
- A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
- Radiotherapy, surgery, or other targeted and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks prior to first administration of the study drug;
- Pregnant or lactating patients;
- Malignant tumors within the past three years (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ);
- Significant comorbidities, including mental illnesses that the investigator believes will adversely affect the patient's participation in the study;
- Those who have received anti-tumor vaccine or have received live vaccine within 4 weeks before the first administration of the investigational drug;
- Patients with known HBV or HCV infection active phase or HBV DNA≥500, or chronic phase with abnormal liver function;
- History of active autoimmune disease (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
- A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; History of interstitial lung disease (except radiation pneumonia without hormone therapy) and non-infectious pneumonia;
- Patients with active infection or who had been treated with systemic immune stimulating factors within 4 weeks prior to enrollment;
- Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
- Previous thyroid dysfunction;
- The investigator did not consider the patient suitable for participation in any other conditions of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment group
|
adebrelimab:1200mg intravenously, Q3W.
Other Names:
dalpiciclib:150mg once a day for 3 weeks and stop for 1 week.
Q4W.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival(PFS)
Time Frame: Up to 3 years
|
PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first).
Assessed according to RECIST v1.1 by investigator.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 3 years
|
ORR is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria.
|
Up to 3 years
|
Overall survival (OS)
Time Frame: Up to 5 years
|
OS is defined as the time between enrollment and the patient's death due to any OS is defined as the time between enrollment and the patient's death due to any cause
|
Up to 5 years
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Up to 3 years
|
Includes the Treatment-Emergent adverse event profile and rates according to the Common Terminology Criteria for Adverse Events version 5.0.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJ-IRB20231105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Adebrelimab
-
Henan Cancer HospitalNot yet recruiting
-
Fujian Cancer HospitalRecruitingOvarian Diseases | Ovarian NeoplasmsChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Fudan UniversityRecruitingCastration-resistant Prostate Cancer | Prostate Cancer MetastaticChina
-
Zhongzheng XiangNot yet recruitingHead and Neck Squamous Cell Carcinoma
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingCldn18.2-positive Advanced Solid TumorChina
-
West China HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityWest China Hospital; Nanfang Hospital, Southern Medical UniversityNot yet recruitingNasopharyngeal Carcinoma | Nasopharyngeal CancerChina
-
Hospital of Stomatology, Wuhan UniversityRecruitingClinical IVb Stage Oral Squamous Cell Carcinomas PatientsChina
-
Ningbo Medical Center Lihuili HospitalRecruiting